Nurix Defies Earnings Miss
Nurix Therapeutics Stock Gains After Q3 Miss, buoyed by transformative Roche deal and pipeline updates
Key Points
Analysts responded with mixed reactions after Nurix's Q3 results, with several updates to price targets and ratings: Truist Financial raised its target to $32, Wells Fargo downgraded to Hold with a $25 target, HC Wainwright reiterated Buy with a $32 target, Oppenheimer initiated coverage with Outperform and a $28 target, and Weiss Ratings issued a Sell rating.
Insider trading activity detailed: Gwenn Hansen sold 5,394 Nurix shares at about $20 each, and CFO Houte Hans Van sold 14,055 shares at about $16.60, with post-sale ownership around 115,005 shares (~$2.3 million) for Hansen and 37,592 shares (~$624,000) for the CFO; both moves were executed under pre-arranged Rule 10b5-1 plans.
Valuation and profitability metrics underscore a challenging balance sheet, with Nurix trading at a negative earnings multiple (P/E around -7.81) and weak profitability indicators (negative net margin around -411%, ROE around -64%). The stock’s 52-week range spans roughly $8.19 to $25.09, and the company has a market cap near $2.55 billion.
Trading day dynamics showed the stock moving higher despite the miss, with Nurix shares changing hands around 1.25 million and trading near $24.69 intraday, signaling investor interest even after the earnings shortfall.
Nurix Therapeutics posted Q3 2026 revenue of $9.04 million and a loss of $0.81 per share, missing analyst estimates and marking a steep 35.6% revenue drop from the same quarter last year, according to TradingView. Yet shares still climbed, trading near $24.69 on volume of about 1.25 million shares — a sign investors are looking past the miss toward a much bigger payday ahead.
That payday is a roughly $700 million upfront payment from Roche, expected next quarter. If it lands, Nurix's cash position would jump to about $1.14 billion, fueling a move into Phase 3 trials for its lead drug, bexobrutideg, reported 247 Wall St.
Revenue Falls but Roche Deal Changes the Math
Nurix's net loss widened to $89.54 million in Q3, up from the prior year, according to TradingView. Revenue came in well below the consensus estimate of $15.29 million. The company burns cash fast — its net margin sits at roughly negative 411%, and its return on equity is around negative 64%, per GuruFocus.
Despite the rough numbers, the Roche collaboration for bexobrutideg is the story investors care about. That deal alone is expected to bring $700 million upfront — non-dilutive cash that does not water down shareholders. Nurix's DEL-AI drug discovery platform has now generated $489 million in total non-dilutive proceeds, with Gilead, Sanofi, and Pfizer also among its partners.
Pipeline Progress: bexobrutideg Heads Toward Phase 3
Bexobrutideg is Nurix's most advanced drug. It targets BTK, a protein involved in blood cancers, and degrades it rather than just blocking it. The drug is currently in Phase 2 trials. The Roche partnership is designed to push it into Phase 3, a major and expensive step toward possible approval, according to 247 Wall St.
Two other drugs are also moving forward. Zelebrudomide and NX-1607 are both in Phase 1 trials. Operating costs are rising as Nurix ramps up spending on trials, contract manufacturers, and new staff to support this growth, per TradingView.
Analysts Split: Upgrades and a Downgrade After the Miss
Wall Street had mixed reactions after the results. Truist Financial raised its price target to $32. HC Wainwright kept its Buy rating with a $32 target. Oppenheimer started coverage with an Outperform rating and a $28 target. But Wells Fargo moved the other way, cutting Nurix to Hold with a $25 target. Weiss Ratings went further, issuing a Sell, according to GuruFocus.
The stock's 52-week range runs from $8.19 to $25.09. Its market cap sits near $2.55 billion, while it trades at a negative price-to-earnings ratio of about -7.81 — typical for a clinical-stage biotech that has not yet turned a profit. Investors are betting on future drugs, not current earnings.
Insiders Sell Shares Under Prearranged Trading Plans
Two Nurix insiders sold stock around the time of the results. Gwenn Hansen sold 5,394 shares at roughly $20 each. CFO Hans Van Houte sold 14,055 shares at about $16.60 per share. Both sales were made under Rule 10b5-1 plans — prearranged schedules set up in advance to avoid any appearance of trading on inside information, per GuruFocus.
After the sales, Hansen held about 115,005 shares, worth roughly $2.3 million. The CFO retained about 37,592 shares, worth around $624,000. Insider selling after a pipeline milestone announcement is not unusual in biotech, but the moves drew attention given the timing of the Roche news.
Sentiment
Mostly PositivePublishers
12
Articles
5
Reach
17
